Simultaneous spectrophotometric determination of lansoprazole and domperidone in capsule dosage form.

Indian J Pharm Sci

Department of Pharmaceutical Chemistry, Sinhgad Institute of Pharmacy, 45-1/2/3, Narhe, Pune - 411 041, India.

Published: January 2008

Two simple, accurate and precise spectrophotometric methods have been developed for simultaneous determination of lansoprazole and domperidone in pharmaceutical dosage form. Method A involves formation of Q-absorbance equation at 256.0 nm (isoabsorptive point) and at 294.2 nm while method B is two wavelength method where 277.6 nm, 302.1 nm were selected as lambda(1) and lambda(2) for determination of lansoprazole and 231.3 nm, 292.0 nm were selected as lambda(1) and lambda(2) for determination of domperidone. Both the methods were validated statistically and recovery studies were carried out. The Beer's law limits for each drug individually and in mixture was within the concentration range of 5-50 mug/ml. Linearity of lansoprazole and domperidone were in the range of 24-36 mug/ml and 8-12 mug/ml, respectively. The proposed methods have been applied successfully to the analysis of the cited drugs either in pure form or in pharmaceutical formulations with good accuracy and precision. The method herein described can be employed for quality control and routine analysis of drugs in pharmaceutical formulations.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2852044PMC
http://dx.doi.org/10.4103/0250-474X.40343DOI Listing

Publication Analysis

Top Keywords

determination lansoprazole
12
lansoprazole domperidone
12
dosage form
8
selected lambda1
8
lambda1 lambda2
8
lambda2 determination
8
pharmaceutical formulations
8
simultaneous spectrophotometric
4
determination
4
spectrophotometric determination
4

Similar Publications

Background: Patients with erosive oesophagitis, and those with persistent symptomatic non-erosive gastro-oesophageal reflux disease, require long-term maintenance treatment with acid-suppressing agents.

Aim: To evaluate the safety of vonoprazan, a potassium-competitive acid blocker, in an integrated analysis of data from clinical trials in adults.

Methods: We included 14 clinical trials of vonoprazan conducted in multiple countries.

View Article and Find Full Text PDF
Article Synopsis
  • - This study aimed to determine if tegoprazan is as effective as lansoprazole in healing erosive esophagitis (EE) within four weeks, with a specific focus on rapid mucosal healing and symptom relief by week two.
  • - In a randomized trial of 218 patients, results showed that tegoprazan had significantly higher healing rates compared to lansoprazole at both two weeks (88.4% vs. 82.6%) and four weeks (95.2% vs. 86.2%).
  • - The findings suggest that tegoprazan is superior to lansoprazole for treating EE, but more research is needed to fully understand its advantages, especially for severe cases
View Article and Find Full Text PDF

Association between proton pump inhibitors and dementia risk: a Mendelian randomization study.

Sci Rep

November 2024

Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, China.

Numerous observational studies suggest associations between proton pump inhibitors (PPIs) and dementia, but causal relationships remain uncertain. Using large-scale genome-wide association study (GWAS) data, we performed univariable Mendelian randomization (UVMR) analysis to assess the causality between five PPI types, and all-cause dementia and its five subtypes. Confounders were controlled through multivariable MR (MVMR) analysis to isolate PPIs' direct effects on dementia.

View Article and Find Full Text PDF
Article Synopsis
  • The efficacy of vonoprazan-based therapies for treating infection was similar across various demographic factors like age, sex, race, and ethnicity.
  • Both dual and triple therapies using vonoprazan showed consistent results compared to lansoprazole-based triple therapy.
  • Factors like BMI, alcohol intake, smoking status, and adherence to the study drug did not significantly affect treatment outcomes.
View Article and Find Full Text PDF

P2X7 is a purinergic receptor physiologically activated by extracellular ATP. Its activation induces proinflammatory responses, including cytokine release, reactive oxygen species formation, and cell death. Previous in vivo experimental models demonstrated that P2X7 blockade has anti-inflammatory effects; however, there are no drugs used in clinical therapy that act on the P2X7 receptor.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!